Pages

▼

Tuesday, 10 February 2026

A maximalist intervention strategy – Alibek’s treatment for regressive autism driven by reactivation of a latent viral infection

Minimalist vs. Maximalist: Matching Art Styles to Your Client’s Personality

Minimalist vs maximalist, the choice is yours


In my last post I introduced the concept of nudge treatments for autism at one extreme, to the sledgehammer at the other.

Today we are looking at the number of treatments used at once. It goes from cautious/minimalist to maximalist.

Dr Ken Alibek is known for his earlier role in the former Soviet biological weapons programme before later working in biodefence and virology in the United States. In recent years, he has proposed that a subset of regressive autism may be driven by latent viral infection and antibody-dependent enhancement (ADE), leading to chronic neuroinflammation.

It is relevant to mention that Dr Alibek has a daughter with autism. That personal connection clearly shapes his interest in identifying a biological mechanism and targeted therapy for a very specific autism. There is nothing unusual about this — many researchers are motivated by personal experience — but it helps explain why his model focuses on a specific immune-mediated, regressive subtype rather than autism as a whole.

His ideas have attracted interest within biomedical autism circles, particularly among parents of children with sudden regression. In mainstream academic medicine, however, the theory remains unproven and largely speculative pending stronger clinical evidence.

Dr Alibek’s approach is not simple polytherapy, but a high-intensity, multi-layer protocol that simultaneously targets viral reactivation, immune activation, inflammation, and gut dysbiosis.

It is a maximalist intervention strategy.

It is very different to Peter’s, step-by-step, personalized polytherapy approach, which looks very cautious when you compare them.

 

The ADE autism hypothesis

Dr Alibek proposes that a subset of regressive autism is driven by latent viral infection in the brain. The viruses implicated are mainly herpesviruses such as HHV-6, CMV, HSV, rubella, or varicella.


These infections occur early in life (in utero or infancy) and persist in a dormant state.
The child produces antibodies, but they are non-neutralising — meaning they bind the virus without fully blocking it.

Later, an immune trigger such as fever or infection reactivates the latent virus. Instead of protecting the child, the existing antibodies facilitate viral entry into immune cells via Fc receptors — the antibody-dependent enhancement (ADE) pathway.

This leads to amplified viral activity inside immune cells.

·        Microglia in the brain become activated.

·        Cytokines and inflammatory mediators are released.

·        Synaptic function is disrupted.

The result is abrupt developmental regression — often described by parents as a sudden “cliff.”


The model attempts to explain regression after fever, immune-triggered worsening, and chronic neuroinflammation seen in some autism studies. It applies specifically to a regressive, immune-sensitive subtype — not to all autism.

 

Appraisal

The model is biologically plausible and internally coherent.
However, ADE has not been demonstrated in herpesviruses in this context, and controlled clinical evidence is lacking.


Clinical improvement on his multi-drug protocol does not by itself validate the ADE mechanism.

For antibody-dependent enhancement (ADE) to occur, three things must be present:

·        The virus must be actively replicating and producing viral particles.

·        Antibodies must bind to those viral particles without fully neutralising them.

·        The antibody–virus complex must then enter immune cells via Fc receptors.

 

In other words, ADE requires active virus in circulation.

A virus that is truly dormant (latent) inside cells cannot trigger ADE, because there are no viral particles available for antibodies to bind.

This has an important implication for treatment.

If the therapy works only while antivirals are being taken, then it is acting as long-term viral suppression — similar to how recurrent herpes infections are managed.

However, if a single 30-day course produces lasting improvement, then something more than simple viral suppression must have occurred. That would suggest either a change in immune regulation or a different underlying mechanism altogether.

 

Lab features that would fit the ADE / viral reactivation subtype

Evidence of herpesvirus reactivation

More meaningful than just high IgG:

  • Positive viral PCR (blood, saliva, CSF if done clinically)
  • Detectable viral DNA load
  • Rising IgG titres over time
  • Positive IgM (though often absent in reactivation)
  • Elevated early antigen antibodies (for EBV, for example)

 

High IgG alone is common in the general population and is not sufficient.

 

Immune Activation Profile

Markers suggesting ongoing immune stimulation:

  • Elevated CD3+ T-cell counts
  • Skewed CD4/CD8 ratio
  • Elevated NK cell activation markers
  • Elevated inflammatory cytokines (IL-6, TNF-α, IL-1β)
  • Elevated CRP (even mildly)

These would support chronic immune activation.

 

Neuroinflammatory Indicators

There is no easy blood test for brain inflammation, but possible supportive markers:

  • Elevated S100B
  • Elevated neopterin
  • Elevated CSF inflammatory markers
  • Elevated serum ferritin (as inflammatory marker)

 

Mast Cell / Histamine Activation

Since the model overlaps with mast-cell activation:

  • Elevated serum tryptase
  • High plasma histamine
  • DAO imbalance
  • Clinical history of allergy, eczema, flushing

 

Clinical Phenotype

Labs alone are not enough. The clinical picture should include:

  • Clear regression after fever or infection
  • Worsening during immune stress
  • Fluctuating course
  • Temporary improvement with anti-inflammatory agents

Without this phenotype, the lab signals are less meaningful.

 

What Would NOT Be Sufficient

  • High HHV-6 IgG alone
  • High VZV IgG alone
  • A single abnormal T-cell number
  • Vague “immune imbalance”

Most adults and children are herpesvirus IgG positive.

 

What would truly support the model

The strongest evidence would be:

1.     Active viral load detected.

2.     Antiviral therapy reduces viral load.

3.     Clinical improvement correlates with viral suppression.

That would be compelling.

 

The initial Alibek therapy can include all of:

 

Antiviral Therapy

  • Valacyclovir
  • Ribavirin

Antibacterial / Antimicrobial

  • Azithromycin
  • Rifaximin 
  • Artemisinin

Antifungal

  • Nystatin
  • Fluconazole

Anti-Inflammatory

  • Ibuprofen

 

Mast Cell / Histamine Modulation

  • Ketotifen
  • Zyrtec (cetirizine)

Gut Support

  • Sodium Butyrate
  • Soluble Fiber
  • Bacillus coagulans probiotic
  • Digestive enzymes
  • Activated charcoal

 

Neuro / Antioxidant Support

  • NAC
  • Omega-3 (EPA/DHA)
  • Magnesium glycinate
  • L-theanine
  • Vitamin C
  • Milk Thistle Extract

 

Methylation / Folate Support

  • Folinic acid
  • Methylcobalamin

General Micronutrients

  • Multivitamin
  • Vitamin D
  • Vitamin K2

 

What is controversial?

When you look at each therapy individually, none are that controversial. All of them are on my list of possible autism therapies, that have at least some solid grounding in science.

What makes the protocol controversial is not any individual drug, but the simultaneous stacking of so many active interventions, which increases risk and makes causal interpretation extremely difficult.

Ribavirin is probably the most controversial element in that protocol.

I actually wrote about ribavirin, back in 2017, but not in relation to a virus. 

eIF4E inhibitors for Autism – Why not Ribavirin?

In 2017 I discussed ribavirin from a very different perspective. My interest was not antiviral activity, but its potential role as an inhibitor of eIF4E, a key downstream component of the mTOR pathway. Overactivity of mTOR/eIF4E signalling has been linked to synaptic protein dysregulation and excitatory/inhibitory imbalance in certain autism models. In that context, ribavirin was considered as a possible targeted modulator of translational control — a pathway-based hypothesis grounded in mouse data.

Dr Alibek’s use of ribavirin sits within a different framework. In his model, ribavirin is part of a broader antiviral strategy aimed at suppressing latent viral reactivation and reducing immune-driven neuroinflammation. The same drug is therefore being used under two very different theories: one targeting synaptic translation mechanisms, the other targeting chronic viral infection.

 

Peter’s 2017 Ribavirin Hypothesis

The reasoning was:

  • mTOR overactivity is implicated in autism.
  • eIF4E is a key downstream node in mTOR signalling.
  • Overexpression of eIF4E causes autism-like phenotypes in mice.
  • Inhibiting eIF4E corrects behaviour in animal models.
  • Ribavirin inhibits eIF4E signalling.
  • Therefore: ribavirin might work as a selective downstream mTOR modulator.

This was:

  • Mechanistic
  • Based on translational control
  • Focused on E/I imbalance
  • Rooted in synaptic protein synthesis

It had nothing to do with viral reactivation.

It was about translation dysregulation.

 

Alibek’s ribavirin usage

In his protocol, ribavirin appears positioned as:

  • A broad-spectrum antiviral
  • Part of an anti-viral / anti-infective stack
  • Targeting presumed chronic viral reactivation

That is a completely different theoretical framework.

Same drug. Different logic.

 

Which Version Is More Biologically Coherent?

Peter’s 2017 argument had:

  • Direct mouse model evidence
  • Clear molecular target (eIF4E)
  • Specific downstream mechanism
  • Defined signalling pathway

Alibek’s usage is:

  • Broader
  • Infection-driven
  • Less specific mechanistically

 

Neither hypothesis has been tested in controlled human clinical trials.

Both are biologically plausible.

Both are unproven.

Both could ultimately be partly right, completely right, or completely wrong.

 

Why Ribavirin Is Still Controversial

  • Ribavirin is not a selective eIF4E inhibitor.
  • It has systemic effects.
  • It is not benign.
  • Human autism trials do not exist.

 

Conclusion

It is not surprising that Dr Alibek’s theory has many followers. I am told that he has many happy clients.

I was struck by the number of simultaneous interventions. There are very many therapies stacked together all at once. 

Because herpes viruses establish lifelong latency (they never leave you), antivirals can only suppress active replication, not eliminate the virus. An important practical question therefore becomes: how often would such therapy need to be repeated?

If families are seeing sustained improvement, then the protocol is working for them in practice — regardless of whether the ADE explanation ultimately proves correct.

I gave up, long ago, thinking about a single standard polytherapy for autism, shifting towards a personalized polytherapy. There is so much variation among people that the more you stack interventions together it becomes inevitable that you will include one that provokes a negative reaction, or indeed no reaction. I favour the use of less interventions, just ones that are beneficial in that unique person. The only way to do that is to go step by step. You also learn from identifying which therapies provoke a negative reaction.

One blog reader in Siberia has a child with very similar therapeutic responses to my son, for example bumetanide and verapamil work very well; but there are also notable differences. For me choline was bad, but it works well in Siberia. 





26 comments:

  1. In ME/CFS Drs Kaufman and Ruhoy have shared a SEPTAD framework of comorbidities. In patients like us who have most of these comorbidities diagnosed by mainstream drs we end up on a regime somewhat similar to one mentioned by Dr Alibek. Drs Kaufman and Ruhoy often share the consensus of more than 700 US Drs who are treating mast cell and long covid etc. In our case azithromycin is given for gut motility and rifaximin is pulsed for SIBO- both by mainstream gastro. Aciclovir is given for viral reactivation by mainstream Immunologist. Cardiologist are treating dysautonomia separately. And Immunoloist are treating mast cell activation. Most drugs are on very low dose due to tolerance issues.. I think Septad frameworks in some autism as well. https://www.healthrising.org/blog/2023/10/12/septad-chronic-fatigue-syndrome-pots-long-covid-kaufman-ruhoy/

    ReplyDelete
  2. The one thing that concerns me as a new patient of his is that my sons lab testing that he ordered didn’t show a ton of active infection. Just slightly elevated cmv and hhv like you mentioned yet it seems everyone is getting the same protocol with some slight variation regardless. There is a group that shares a lot so we all see and discuss the meds. It almost seems like it could be kind of a throw it at the wall and see wha sticks sort of thing

    ReplyDelete
    Replies
    1. Yes, but if you start all these meds at once, how do ever know which are doing any good? My son would respond to some of these things, but they have nothing to do with a viral infection.

      Delete
    2. Petar Vuckovic
      Здравствуйте теория др Кеннета такая да ребёнку больше могут навредить патогены микроорганизмы, чем лекарства которые он назначает... Он явно говорит что аутизм, это путь который видеть к онкологии, поэтому нужно лечить!!! Терапии очень тяжёлая, трудно выдержать до конца!!!

      Delete
    3. “Hello. Dr. Kenneth’s theory is that pathogenic microorganisms can harm the child more than the medications he prescribes. He clearly says that autism is a pathway that leads to oncology (cancer), therefore it must be treated!!! The therapies are very difficult, and it is hard to endure them until the end!!!”

      Petar, there is indeed some overlap between certain autism-related genes and tumor suppressor genes. PTEN is the classic example. Children with PTEN mutations can have both severe autism and an increased cancer risk. However, such cases are rare, and most autistic children do not develop cancer. Among readers of this blog, I am aware of only one child who later died from cancer, which was leukemia.

      Certain viruses are clearly linked to specific cancers, for example:

      Epstein–Barr virus → lymphoma and nasopharyngeal cancer
      HPV → cervical and other cancers
      Hepatitis B and C → liver cancer

      However, Epstein–Barr virus infection is extremely common, and the vast majority of carriers never develop cancer.

      It is reasonable to investigate whether infections, immune dysfunction, or other biological factors contribute to symptoms in some children. However, I do not think fear of cancer should be used as a justification for pursuing or avoiding specific autism therapies.

      Treatment decisions should be based on evidence, clinical judgment, and the individual child’s needs, rather than fear of unlikely outcomes.

      Delete
  3. My son had a regression in one day. I even remember the date, February 9, 2012. He was 19 months old. He lost his speech, his comprehension of speech, his play skills, and eye contact. Yes, before that he had roseola (herpesvirus 6) with a fever of 40°C (104°F).

    ReplyDelete
    Replies
    1. Your son very much fits the type of autism that Alibek is trying to treat. It was a one day regression, not gradual. Did he regain his speech later?

      Delete
    2. An alternative explanation comes from Dr. Richard Kelley at Johns Hopkins, who has studied regression in autism for many years. His model focuses on mitochondrial function rather than persistent immune activation.
      Mitochondria are the structures inside cells that produce energy. The brain, especially the parts responsible for speech and social interaction, has very high energy requirements during early development. Some children appear to develop normally because their mitochondria can meet ordinary energy needs, but they may have limited reserve capacity.
      A viral infection such as HHV-6, particularly with a high fever of 40 °C, places enormous stress on the brain. Fever increases energy demand, while infection and inflammation simultaneously impair mitochondrial energy production. This can create an acute energy shortage in vulnerable neurons.
      Synapses, which allow neurons to communicate, require large amounts of energy and are affected first. When synapses cannot produce enough energy, communication between neurons fails, leading to sudden loss of speech, comprehension, eye contact, and play skills.
      In this model, the regression reflects a functional energy failure rather than permanent structural damage. The neurons often remain alive, which helps explain why some recovery may occur over time.
      This differs from Dr. Alibek’s explanation, which emphasizes persistent immune activation in the brain. Dr. Kelley’s model instead places mitochondrial energy failure at the center, with the infection acting as the trigger that pushes an already vulnerable energy system past its limit.

      Delete
    3. No, his speech did not return. The son remained non-verbal. No protocols helped. We visited Dr. Antonucci for several years. There were various protocols. No genetic abnormalities were found; we had three whole exome sequencing tests and a chromosomal microarray analysis. No mitochondrial issues were detected either. The child was examined by geneticists for mitochondrial dysfunction. All indicators were normal.

      Delete
    4. Thank you for sharing your son’s history. Many parents have described a very similar pattern — completely normal development, followed by a sudden regression in a single day associated with a high fever or viral illness such as HHV-6.

      For many years, this type of regression was poorly understood, and some physicians questioned whether children had truly developed normally beforehand. However, it is now widely recognized that sudden regression after illness does occur in a subset of children later diagnosed with autism.

      Unfortunately, many families also report that speech does not return, even after extensive testing and multiple treatment attempts.

      This reflects the limitations of current medical testing, which cannot directly measure synaptic function or energy production inside living brain cells. Standard genetic testing, mitochondrial testing, and MRI scans often appear normal in these children, because much of the dysfunction is functional rather than structural and cannot be detected with current tools.

      Some physicians believe regression represents a period of acute metabolic and inflammatory stress on the brain, during which neurons remain alive but function poorly. For this reason, some doctors — particularly in Russia and Ukraine — emphasize immediate intervention, focusing on controlling fever, reducing inflammation, treating infection if present, and supporting mitochondrial energy metabolism.

      The goal is to stabilize neuronal function during this vulnerable period. However, there is currently no universally accepted treatment protocol, and outcomes vary greatly between individuals.

      Your experience is, sadly, not uncommon. Many families around the world have faced the same sudden regression following illness, normal medical tests, and persistent impairment years later.

      I also looked into Dr Kelley’s work many years ago. While his model helped explain a possible mechanism, it was disappointing that no clearly effective reparative therapy existed, and most recommendations focused on metabolic support and preventing further stress rather than reversing the regression itself.

      Delete
    5. Not that its any consolation but I have found ethosuximide helpful for speech. However, the side effects where too much for my son.

      https://brainfoundation.org/synchrony-symposia/synchrony-2025-highlights/

      https://patents.google.com/patent/WO2023239964A1/en

      Delete
  4. Is Ibuprofen safe for everyday use?
    Thank you!

    ReplyDelete
    Replies
    1. Ibuprofen can be used for a few weeks, but daily use for a month should ideally be supervised by a physician.
      It may help reduce neuroinflammation, but longer use increases risks to the stomach and kidneys.
      Celecoxib is often preferred for longer use because it is gentler on the stomach.
      However, it still carries some kidney and cardiovascular risks.
      The safest approach is the lowest effective dose under medical guidance.

      Delete
  5. Regarding virus-induced autism and immune system havoc, I'd say long covid research is a great place to learn more.

    Long covid features a lot of things mentioned above or in autism such as viral reservoirs, latent virus reactivation, MCAS, mTOR activation, inflammation, autoimmune disorders, deficient autophagy, brain fog, serotonin deficiency, dysautonomia, gut dysbiosis, muscle weakness, speech issues and oxidative stress. Long covid is in the same post-infection category as tick-borne diseases/lyme and ME/CFS, and notably also both MS and Sjogrens' syndrome have now been tied to a viral origin.

    While the research on long covid is still going into all directions, the most interesting findings are those on elevated IFN-y levels, a deficient number of peroxisomes in cells, and macrophages going rouge. This triad has massive effects on immunity, metabolism, tissue repair and garbage management (=inflammaging). Currently three different independent clinical studies on JAK inhibitors are initiated (IFN-y initiates JAK-STAT signaling in macrophages), but I must admit the safety profile looks nasty...
    A different treatment approach could be sodium phenylbutyrate (4-PBA), which originally is an orphan drug for urea cycle disorders. 4-PBA also happens to raise the number of peroxisomes in macrophages, which seems to do the trick in animal models of both long covid and herpes simplex encephalitis. It is being studied in a range of brain disorders, and is approved for children.

    /L

    ReplyDelete
  6. Hello Peter, have you had any encounters with PICA--we have heard it can be because of low Iron and Zinc--we have supplemented this, but still finding he is wanting to eat foreign objects. Any info would be of help . thanks, Jeryl

    ReplyDelete
    Replies
    1. Hello Jeryl, pica is quite common in autism, and you are right that low iron and zinc are the most frequent contributors.
      Since you have already supplemented, it is worth checking ferritin, as “normal” levels can still be too low.

      Aim for ferritin above 40–50 ng/mL. You can safely go to 100.

      Zinc–copper balance can also matter, but I would not add copper unless testing shows it is low. Copper and zinc work in opposition.

      In many children, pica is partly sensory-driven, so nutritional fixes alone may not fully resolve it.

      Reflux or general gut discomfort can also drive unusual eating behaviors, so that is worth considering as well.

      Some parents report changes with high-dose or injected B12, possibly increasing sensory-seeking in a subset of children.
      This is not well proven, but it may be worth noting if the timing fits.

      Delete
  7. Hi Peter, I have consulted dr Ken Alibek for a year now.. Though my child did not see much gains, but have witnessed many kids getting benefitted. One of the primary reasons people feel his protocol helped is that he fearlessly adds many powerful supplements, and some do help.

    In autism community, it's a taboo to do many things together, he challenged that view. Also, I know some parents who did not have sudden regression case, but still benefitted greatly from dr Ken ( though the parent had already worked on the core issues a lot).

    I had a question about regression, many kids may have immune priming in utero , from mothers who may have immune activation, heavy metals or infections during pregnancy, so the child kind of got subjected to the harsh environment in utero ( which the sudden regression kids apparently are subjected to after birth).. So in that sense, even those kids can be called as sudden regression , they regressed even before birth?

    ReplyDelete
    Replies
    1. I think you raise a very interesting question about prenatal influences, particularly maternal immune activation during pregnancy.

      There is substantial research suggesting that maternal infections and inflammatory responses can influence fetal brain development. Potential mechanisms include changes in cytokine signalling, microglial development, synaptic formation and neuronal connectivity.

      This raises the possibility that some children who develop autism without obvious postnatal regression may already have experienced significant neurodevelopmental disruption before birth.

      I would distinguish between the timing of the original biological disturbance and the timing when its consequences become clinically apparent.

      Rett syndrome provides a particularly interesting example.

      In classic Rett syndrome, the MECP2 mutation is present from conception. Yet development can initially appear relatively normal, followed by developmental stagnation and regression, typically during the first few years of life.

      Why does this happen?

      MECP2 becomes increasingly important as neurons mature and neuronal networks develop. The genetic abnormality is present from the beginning, but its functional consequences become increasingly significant as the developing brain becomes more dependent on the processes that MECP2 regulates.

      In other words, the biological problem precedes the clinical deterioration, sometimes by many months.

      I wonder whether a similar principle might apply to some forms of autism, although the underlying mechanisms would obviously be different.

      Perhaps some children have prenatal biological abnormalities, whether involving immune activation, inflammation, metabolism or other processes, which are initially compensated for. As the brain develops and its requirements change, those abnormalities become increasingly consequential.

      This might help explain why some children show differences from infancy, others experience a developmental plateau, and others appear to develop normally before subsequently losing acquired abilities.

      I would therefore distinguish three things:

      When the original biological abnormality arises.

      When the developing brain becomes increasingly dependent on the affected biological function.

      When the consequences become sufficiently significant to be recognised clinically.

      This also has implications for precision medicine. Rather than focusing exclusively on whether a child experienced regression, perhaps we should be asking what biological processes were disrupted, when they were disrupted, and whether those abnormalities are still present and potentially treatable.

      Of course, maternal immune activation is a risk mechanism, not an established explanation for any particular child's autism. And Rett syndrome is a specific genetic disorder, not a direct model for autism generally.

      Nevertheless, I think the developmental principle is worth exploring: the onset of a biological problem and the onset of its clinical consequences do not necessarily occur at the same time.

      Delete
    2. Our oldest son, who has severe autism, we initially suspected that vaccines or antibiotics had triggered his regression.

      When our second son was born premature and with intrauterine growth restriction (IUGR) we were in the middle of COVID quarantine and deliberately avoided all vaccines and antibiotics. Yet, even without them, we noticed something was off as he began missing his developmental milestones. Around that time, my oldest son was participating in a leucovorin trial. His younger brother ended up sneaking sips from a sippy cup containing crushed leucovorin, and remarkably, he started talking. Even so, he still faced significant struggles.

      By the time our third son arrived, our approach had shifted again; because of the IUGR history, my wife took aspirin during the pregnancy, and our third son is neurotypical. I believe all three boys carry the folate autoantibodies, but the aspirin used during the third pregnancy helped dampen the maternal immune activation. Furthermore, the p-cresol levels decrease from 4000 for the eldest, 2000 for middle, and 200 for youngest.

      Side note, I guess pectin lowers p-cresol...

      Digestion-resistant proteins support the healthy metabolite profiles associated with plant-based diets

      https://www.pnas.org/doi/10.1073/pnas.2605226123#core-collateral-purchase-access

      Delete
    3. Thank you for sharing this.

      Maternal aspirin and neurodevelopment

      Your observation about your third pregnancy raises an interesting question. Low-dose aspirin is already used during pregnancy to reduce pre-eclampsia risk in women who meet the clinical criteria.

      I recently wrote about aspirin and omega-3 fatty acids in relation to resolvins, FPR2 and the active resolution of inflammation. Aspirin can influence the production of specialised pro-resolving lipid mediators. It is conceivable that modifying inflammatory signalling at the maternal–placental interface could influence fetal neurodevelopment.

      I am interested in the prevention and minimization of severity of autism. I had thought Reye’s syndrome would preclude its use during pregnancy, but this is not seen as a risk.

      We should add it to the list.

      Pectin and p-cresol

      The paper you linked is interesting.

      It investigates how dietary fibre and digestion-resistant proteins interact to influence gut microbial metabolism. One finding was that soluble fibres, including pectin, reduced the production of tyrosine-derived phenolic metabolites, including p-cresol sulfate, in mouse experiments.

      This is interesting because it suggests a different objective from simply increasing butyrate production with prebiotic fibres such as inulin or resistant starch. We may be able to influence both carbohydrate fermentation and protein fermentation.

      Delete
    4. Here is the full link. Even during fasting the microbiome is eating the tyrosine in the mucin to produce p-cresol. Pectin and inulin stop this behavior.

      https://drive.google.com/file/d/1leiPbfdOs9VDRG6es2r3BzvW6P2C8M1K/view?usp=drivesdk

      Delete
  8. Dear Peter,

    Thank you so much for your blog. I have been studying your work extensively, but the more I learn, the more overwhelmed I feel about where to begin.

    My child is 9 years old. At age 5, he developed prominent hand stimming, poor attention, constant hyperactivity, regression-like behaviours, social withdrawal, fears, and sleep disturbances. He gradually improved, which I attribute to my intensive company. Our doctor suspects high-functioning autism. He can speak but struggles with meaningful communication, often remaining absorbed in his own world and responding mainly when interested. He struggles to remember classmates' names, despite being able to recite long poems, sing complex songs, and remember detailed movie and TV plots.

    Six months ago, after a month of high-dose supplements prescribed by a functional medicine practitioner, he developed severe behavioural and psychiatric symptoms, including aggression and headaches, and has not fully recovered. The supplements included vitamin D3 (10,000 IU/day for 15 days, then 8,000 IU/day for 15 days), vitamin C, selenium, magnesium, digestive enzymes, probiotics, a complex amino acid blend(including glutamic acid), and NAC.

    We have completed extensive testing:

    1、WGS: Variants in BRWD3, CACNA1B, ITPR1, GRIA2, etc., all classified as VUS.

    2、EEG and brain MRI: Normal.

    3、Metabolic screening: No classic organic aciduria, but elevated 3-hydroxybutyrate, 3-hydroxyisovalerate, oxalate, 3-hydroxyphenylacetate, and 3-hydroxyglutarate.

    4、CSF: Normal folate; negative autoimmune encephalitis panel.

    5、Homocysteine: Persistently low for three years.

    He has no obvious gastrointestinal symptoms and has regular bowel movements.

    I feel quite lost about the next steps. Would you suggest considering NAC, memantine, bumetanide, suramin, or intranasal oxytocin in a particular order, or prioritizing ADHD treatment instead?

    I would be deeply grateful for any guidance you could offer. Thank you for your time and generosity.

    ReplyDelete
    Replies
    1. I am particularly concerned about the vitamin D supplementation. Your child received an average of 9,000 IU daily for a month. For comparison, the recommended intake for children aged 9–18 is 600 IU, with an upper intake level of 4,000 IU.

      Excessive vitamin D can cause hypercalcaemia (elevated blood calcium). This can produce irritability, agitation, confusion, behavioural changes, headaches, fatigue, poor appetite and sleep disturbances. I would want calcium, PTH, kidney function and vitamin D levels investigated. A normal vitamin D result six months later would not exclude an earlier episode.

      There is also an interesting genetic finding. CACNA1B encodes the CaV2.2 N-type voltage-gated calcium channel, which regulates calcium entry into nerve terminals and neurotransmitter release. However, this is a VUS, and it does not regulate blood calcium.

      I would also investigate the other supplements:

      Probiotics: Negative effects are possible, for example BioGaia Gastrus contains L. reuteri DSM 17938 and ATCC PTA 6475. The latter can produce histamine. This has immunomodulatory effects, although individual responses may differ. Some readers of this blog experienced the negative effects.

      NAC: Some participants in autism trials have experienced irritability and agitation. It is not universally beneficial.

      Vitamin C: High doses can increase oxalate production, relevant given the elevated urinary oxalate.

      Selenium: Excessive intake can cause neurological and systemic toxicity.

      Magnesium: Generally well tolerated, but excessive doses can cause problems, particularly with impaired kidney function.

      Digestive enzymes: Less likely to explain prolonged behavioural deterioration.

      I am also interested in the timing of the developmental changes. Autism is a neurodevelopmental condition, although it may not become apparent until later. Genuine loss of previously acquired skills at age five deserves investigation for neurological and metabolic causes.

      I would not rush into trying NAC, memantine, bumetanide or other experimental treatments until the child has fully recovered. Other parents have reported prolonged negative responses to supplements, including folinic acid and calcium, despite positive experiences in other children.

      Persistently low homocysteine also deserves investigation, but does not automatically indicate a methylation problem.

      Finally, I would be cautious about interpreting the organic acid results. Commercial organic acid tests popular with functional medicine practitioners are not necessarily equivalent to clinically validated hospital metabolic investigations. I would recommend having the original results reviewed by a specialist in inherited metabolic disorders.

      My priority would be to investigate the possible consequences of the high-dose vitamin D exposure and establish what caused the deterioration before introducing anything else.

      Delete
    2. Thank you very much for your kind reply,Peter

      Over the past several months, my child has been gradually recovering from the severe behavioural and neuropsychiatric symptoms that developed after taking various supplements.

      A few days ago, we tried giving him NAC (600 mg daily), and several of these symptoms reappeared, including aggressive behaviour, sensitivity to noise, eye-picking, fearfulness, and difficulties interacting with peers. After discontinuing NAC, his symptoms began to improve gradually once again.

      This has led us to wonder whether NAC may also have contributed to the regression he experienced following the previous supplementation regimen.

      May I kindly ask for your thoughts on whether such an adverse reaction to NAC could suggest underlying abnormalities in methylation, the transsulfuration pathway, glutamate signalling, or calcium channel function?

      I would be truly grateful for any insights or guidance you could offer.

      Thank you again for your time, kindness, and thoughtful advice.

      Delete
    3. and you mentioned that we should pay special attention to the gene CACNA1B. I have found very limited literature on it so far. Could you kindly advise how we should approach this gene? Many thanks for your guidance.

      Delete
    4. CACNA1B encodes the alpha-1B subunit of the CaV2.2 N-type voltage-gated calcium channel. These channels have an important role in the brain because they regulate calcium entry into presynaptic nerve terminals and consequently the release of neurotransmitters. They are therefore central to communication between neurons.

      There is an established, although still relatively limited, human genetic association between CACNA1B and a neurological disorder involving progressive epilepsy and movement abnormalities.

      The key paper is:
      Gorman et al. (2019), Bi-allelic Loss-of-Function CACNA1B Mutations in Progressive Epilepsy-Dyskinesia (PMID: 30982612).

      The researchers identified six affected children from three unrelated families with biallelic loss-of-function variants. Their clinical presentation included severe developmental delay, epileptic encephalopathy, regression and hyperkinetic movement disorders.

      A further case was reported by Yu et al. in 2024 (PMID: 39005920).

      How does this relate to your child?

      Your son clearly does not have the full-blown neurological disorder described in these publications. He has a much milder presentation, without seizures or the characteristic movement abnormalities.

      This is important when interpreting his genetic result.
      The established CACNA1B-associated disorder follows an autosomal recessive inheritance pattern, meaning that typically both copies of the gene must carry pathogenic variants. A single variant would not cause this established disorder.

      However, I would not automatically conclude that a single variant has no biological effect. It is conceivable that a variant could produce a more modest alteration in CACNA1B expression or CaV2.2 channel function, potentially influencing neuronal communication without causing the severe neurological syndrome.

      We simply do not know whether this is happening in your son's case.

      This is also why the laboratory has classified the finding as a Variant of Uncertain Significance (VUS). The available evidence is insufficient to establish whether it is pathogenic or benign. It does not mean that the variant is necessarily harmless.

      The possible connection with vitamin D

      Your son received very high doses of vitamin D before the behavioural deterioration: approximately 9,000 IU daily for a month.

      Vitamin D has effects beyond regulating calcium absorption from the intestine. Its active metabolite, calcitriol, also participates in neuronal calcium signalling and can influence the activity and expression of voltage-gated calcium channels.
      There is experimental evidence of vitamin D-dependent changes in neuronal calcium-channel activity, although much of this research concerns L-type rather than N-type channels. Excessive vitamin D exposure could have disturbed neuronal calcium signalling, potentially interacting with an existing genetic vulnerability.

      I would not assume that CACNA1B explains the underlying autism. However, it is worth investigating whether a genetic vulnerability might influence susceptibility to particular physiological disturbances.

      Could you provide some additional genetic information?
      In particular:
      • The exact CACNA1B variant, using HGVS notation.
      • Whether either parent carries the same variant.

      Genetic science is evolving rapidly. As more patients are identified, population databases improve and functional studies become available, our understanding of individual variants can change. A VUS today may eventually be reclassified as likely pathogenic, pathogenic or benign.
      I would therefore not dismiss this finding simply because your son's presentation does not resemble the severe neurological disorder already described. Equally, we should not assume that the variant is responsible for his difficulties without supporting evidence.

      I suggest you thoroughly investigate the gene now, draw any conclusions and then move on. If the science changes, a good lab will automatically update you later. This has been the experience of some readers of this blog, when the status of a mutation shifted from VUS.

      Delete

Post a comment